BARD1 Life Sciences (ASX:BD1), a medical technology company developing non-invasive cancer diagnostics, has announced the appointment of prominent Australian scientist Professor Allan Cripps as an Independent Non-Executive Director.
BARD1 Chairman, Peter Gunzburg, said, “We are extremely pleased to welcome Allan to BARD1’s Board of Directors. He brings scientific expertise and diagnostics development experience, which combined with his organisational leadership, governance skills and extensive industry networks will be an asset to our Company as we move towards our vision of building a leading Australian cancer diagnostics company.”
Professor Allan Cripps AO is an academic, clinical scientist and health services leader, having made contributions in immunology, diagnostics and health services delivery.
From 2005 to 2016, Professor Cripps was the Pro-Vice-Chancellor (Health) at Griffith University and he is currently a research professor at the university, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland.
Professor Cripps has published over 300 peer-reviewed scientific papers, presented at numerous international scientific conferences, received over $17 million in government and industry grants and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management.
In 2015, Professor Cripps was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation.
“I am delighted to join the BARD1 Board and look forward to contributing to the successful commercialisation of the Company’s diagnostic technology and working with management to advance its cancer diagnostics pipeline into diagnostic laboratories to benefit patients through earlier diagnosis,” said Professor Cripps.
BARD1 said it is progressing the optimisation phase of its BARD1 auto-antibody assay on the Luminex platform with Thermo Fisher Scientific.